S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE)

By sjmartinez • May 2, 2025

Saeed A, Colby S, Oberstein PE, Duda DG, Park R, Agarwal R, Figueroa-Moseley C, Vaidya R, Unger JM, Guthrie KA, Rocha FG, Senthil M, Safyan RA, Wainberg ZA, Iqbal S, Chiorean EG, Philip PA. S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE). Future Oncol. 2025 May;21(11):1325-1331. doi: 10.1080/14796694.2025.2485020. Epub 2025 Mar 28. PMID: 40155326.

Tags: anti-programmed death-1, combined positive score, esophageal cancer, gastric, gastroesophageal junction, Hematology/Oncology, immunotherapy, paclitaxel, Publications, ramucirumab, vascular endothelial growth factor

Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting

Pasricha ND, Kim SK, Farooq AV, Lindgren ES, Yan R, Seitzman GD, Chan MF, Shantha JG, Skondra D, Jeng BH, Chamberlain WD, Colby KA, Goldstein[...]

Evolving Use of Circulating Tumor DNA for HPV+ Oropharyngeal Carcinoma: Consensus Recommendations From the California Head and Neck Consortium

Ho AS, Moyers JT, Attarian S, Banker R, Birkeland A, Chen MM, Coffey CS, Guo T, Haidar Y, Harris JP, Holsinger FC, Inman J, Jang[...]

Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop

Merryman RW, Rutherford SC, Ansell SM, Armand P, Leonard JP, Nastoupil L, Smith SM, Timmerman JM, Zelenetz AD, Gutierrez M, Béguelin W, Casulo C, Cerhan[...]